Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kamada ( (IL:KMDA) ) has shared an announcement.
On January 7, 2026, Kamada issued 2026 financial guidance projecting revenues of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, implying year-over-year increases of about 13% in revenue and 23% in adjusted EBITDA based on the mid-point of its 2025 outlook. The company said the 2026 targets are driven entirely by organic growth across its proprietary plasma-therapy portfolio and its distribution segment, including further expansion in U.S. and ex-U.S. markets, launches of additional biosimilars in Israel, growth in the MENA region, and initial sales of normal source plasma from its Texas collection centers. Kamada also affirmed its 2025 guidance of $178 million to $182 million in revenues and $40 million to $44 million in adjusted EBITDA and expects to close 2025 with about $75 million in cash, underscoring confidence in its commercial momentum and cash generation even as a reduced GLASSIA royalty rate from Takeda begins to weigh on 2026 results. Management emphasized that strategic business development and M&A remain priorities to augment the existing portfolio and leverage Kamada’s commercial and manufacturing infrastructure for sustained profitable expansion.
The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company focused on specialty plasma-derived therapies and treatments for rare and serious conditions. The company markets a portfolio that includes six FDA-approved plasma-derived products, such as KEDRAB, GLASSIA, CYTOGAM, VARIZIG, WINRHO SDF and HEPAGAM B, along with KAMRAB and equine-based anti-snake venom products, and also distributes in-licensed biopharmaceuticals and biosimilars in Israel and the MENA region. Kamada is expanding its vertically integrated plasma collection operations through three U.S. centers in Texas and pursues business development and M&A to broaden its marketed portfolio and support long-term profitable growth.
Average Trading Volume: 89,744
Technical Sentiment Signal: Buy
Current Market Cap: ILs1.3B
For a thorough assessment of KMDA stock, go to TipRanks’ Stock Analysis page.